Connect your AI

NewAmsterdam Pharma Company NAMS PP&E (Net)

PP&E (Net) at other companies

Merck & Co.MRK

$25.43B+2.6%

AmgenAMGN

$8.22B+23.0%

Eli LillyLLY

$26.54B+43.7%

Denali Therapeutics Inc.DNLI

$51.73M-10.5%

Other financials

Income statement

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

Market cap$3.67B+63.7%

Profitability

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is NewAmsterdam Pharma Company's PP&E (net)?: NewAmsterdam Pharma Company (NAMS) reported PP&E (net) of $379K in Q1 2026.
How has NewAmsterdam Pharma Company's PP&E (net) changed year-over-year?: NewAmsterdam Pharma Company's PP&E (net) increased by 59.2% year-over-year, from $238K to $379K.
What is the long-term trend for NewAmsterdam Pharma Company's PP&E (net)?: Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's PP&E (net) has grown at a 124.2% compound annual growth rate (CAGR), from $34K to $383K.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.